Browse by author
Lookup NU author(s): Dr Ian Brotherick,
Dr Brian Shenton,
Dr Brian Angus,
Professor Thomas Lennard
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In order to assess the specificity of biotinylated anti-c-erbB-3 antibody, screening was performed on a series of tumour cell lines and lymphocytes. Staining was found to be consistent, with good reproducibility. Twenty-nine consecutive breast cancer samples were obtained from women treated with tamoxifen and undergoing elective mastectomy. Twenty-eight invasive ductal carcinomas and 1 DCIS were stained for c-erbB-3 expression: 2 were grade I (Bloom and Richardson), 15 grade II, and 11 grade III tumours, 1 being unclassified; 16 were axillary node positive and 10 node negative; in 2 cases no nodes were sampled. Tumours examined by flow cytometry were stained with cytokeratin FITC antibody and the cytokeratin-positive population gated. Using Mann-Whitney analysis no association was seen between c-erbB-3 expression and Bloom and Richardson grade or axillary node status. In the tumour samples c-erbB-3 expression was found to show an association with EGF-R (P = 0.021 r(2) = 0.16), PgR (P = 0.02, r(2) = 0.16), c-myc (P <0.0001, P = 0.5), c-jun (P = 0.001, r(2) = 0.4) and c-fos (P = 0.001, r(2) = 0.5) but not with c-erbB-2 (P = 0.2, r(2) = 0.06), ER (P = 0.4, r(2) = 0.02) or p53 1801 (P = 0.05, r(2) = 0.2). Expression of c-erbB-3 may not be an independent marker of prognosis, but it is associated with other markers of poor prognosis and early cellular events linked with aberrant growth and differentiation.
Author(s): Brotherick I, Shenton BK, Angus B, Waite IS, Horne CHW, Lennard TWJ
Publication type: Article
Publication status: Published
Journal: Cancer Immunology, Immunotherapy
Print publication date: 01/11/1995
ISSN (print): 0340-7004
ISSN (electronic): 1432-0851
Altmetrics provided by Altmetric